

October 5, 2015



ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results

LOS ANGELES, CA -- (Marketwired) -- 10/05/15 -- ITUS Corporation ("[ITUS](#)") (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, in collaboration with The Wistar Institute, a National Cancer Institute-designated Cancer Center, has achieved very favorable initial results in a cancer biomarker study, successfully demonstrating the efficacy of Anixa's cancer screening technology. Wistar evaluated blood samples from a small group of patients with differing severities of breast cancer to determine the presence or absence of unique and anomalous biomarkers. Wistar also studied blood samples from a small group of healthy patients. The initial results showed the presence of the biomarkers in 100% of the cancer patients tested. Equally as important, none of the healthy patient blood samples contained the biomarkers.

"Although the number of patients initially studied was relatively small, we could not have asked for better results," said Dr. Amit Kumar, ITUS's Vice-Chairman and Anixa's CEO. "We have already begun our next study to finalize our proprietary methodology and protocols and apply them to much larger groups of patients across multiples types of tumor based cancers and healthy controls. Based upon the outstanding results we have seen thus far, we are extremely optimistic about the prospects of using these biomarkers for our cancer screening tests. As we expand the number of samples in our study, we plan to publish the data in peer-reviewed scientific journals and present the results at scientific conferences."

In July of 2015, Anixa announced its collaboration with Wistar - a leader in cancer, immunology, and infectious disease research, located in Philadelphia, Pennsylvania - to develop non-invasive, highly accurate, cost effective cancer screening tests, with the intention of bringing its first test to market within eighteen months.

ITUS Corporation

[ITUS](#) funds, develops, acquires, and licenses emerging technologies in areas such as High-Tech, Biotechnology, Life Sciences, and Informatics. The Company's wholly owned subsidiary, Anixa Diagnostics, is developing non-invasive, cancer screening tests. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2014 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

[ITUS Corporation](#): FOCUSED ON INNOVATION™

Contact:
Dean Krouch
310-484-5184
dkrouch@ITUScorp.com

Source: ITUS Corporation